|
|
|
| |
|
|
| |
The latest oncology news from News Medical |
|
|
|
 | | |  Faster biological aging may help explain rising cancer rates in younger adults A new study found that later birth cohorts showed greater biological aging, measured by systemic age-gap clocks. Greater biological aging was associated with higher early-onset solid cancer risk, especially lung, gastrointestinal, and uterine cancers. | | | | |  Blood protein clocks flag higher risks of death and chronic disease Proteomic age clocks applied to two European cohorts linked faster biological aging with smoking, alcohol use, physical inactivity, all-cause mortality, cardiovascular disease, dementia, and several cancers. The Global proteomic clock predicted mortality as well as established lifestyle risk factors, while organ-specific clocks showed stronger links with related cancers of the kidney, lung, and stomach. | |
|
|
| | | | |  A study led by a researcher based at King's College London and McMaster University in Canada reveals how CAR-T cell therapy, a treatment that engineers a patient's own immune cells to recognize and attack cancer, could be used to treat glioblastoma. | | | | |  A team led by researchers from the German Cancer Research Center (DKFZ) and the HI-STEM* Stem Cell Institute has discovered a promising new approach to treating advanced colorectal cancer. | | | | |  For more than two decades, precision oncology has been promoted as the future of cancer treatment, matching therapies to the unique biology of a patient's tumor. | | | | |  A team of researchers at the University of Warwick and Monash University has solved a puzzle that's stumped drug developers for decades: how bacteria naturally create multiple versions of powerful cancer therapies. | | | | |  Lung cancer remains the leading cause of cancer-related deaths worldwide and is generally thought to arise from mutations acquired over a lifetime through environmental exposures. | | | | | Results of the ongoing eNRGy trial, a single-arm, multicenter, global phase 2 clinical trial evaluating zenocutuzumab in solid tumors positive for Neuregulin 1 (NRG1) gene fusions, reported manageable side effects and clinically meaningful efficacy – including a near doubling of progression-free survival compared to expectations with standard of care – in previously treated patients with advanced NRG1-positive cholangiocarcinoma. | | | | | New research has found that digital breast tomosynthesis (DBT) availability at breast imaging facilities is similar across low- and high-deprivation areas, but facilities in low-deprivation areas are significantly more likely to offer weekend appointments, which may impact access for traditionally underserved populations. | |
|
|
|
|
|
|
|
